CD4 and neoplasm: For example, agonist molecules such as DTA-1, a Rat IgG2b antibody specific for murine GITR, have been shown to be highly effective at promoting tumor rejection in specific tumor models and promoting potent antitumor CD4 and CD8 T cell responses [8–10].